Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00504790 | Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer | PHASE1 | COMPLETED | 39 | — | — | Jun 25, 2007 | May 8, 2012 | Jul 12, 2018 | 3 | United States |
| Arm | Type | Description |
|---|---|---|
| GSK923295 | EXPERIMENTAL | anti-mitotic compound under study |
| Name | Type | Description |
|---|---|---|
| GSK923295 | DRUG | anti-mitotic compound |
Inclusion Criteria: * Signed, written informed consent provided. * a) Stage 1 Subjects: Histologically or cytologically confirmed diagnosis of solid tumor malignancy that is not responsive to accepted standard therapies, or for which there is no standard therapy. b) Stage 2 Subjects: Histologica...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |